Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Entresto patent expiration greece?

See the DrugPatentWatch profile for Entresto

When does the Entresto (sacubitril/valsartan) patent expire in Greece?

I don’t have enough provided information to give a reliable Greece-specific Entresto patent-expiration date. Patent expiry in Greece depends on the exact patent(s) that protect Entresto there (including secondary patents and any supplemental protection, if applicable), and on national status in the Greek registry.

How do you check Entresto patent status specifically for Greece?

To find the correct Greece expiration date, you typically need to:
1. Identify the specific European/Greek patents covering Entresto (primary formulation/compound patents and follow-on patents).
2. Check whether each patent is still in force in Greece (and whether it has expired or been terminated).
3. Look for any additional protection mechanisms that may extend market exclusivity beyond the base patent (these are jurisdiction- and status-dependent).

What can change the “expiration date” people search for?

Search results for “Entresto patent expiration” often mix different concepts:
- Base patent expiry (the end of the patent term for a specific patent).
- Expiry of later “follow-on” patents (changes to dosing forms, formulations, combinations, or methods).
- Regulatory exclusivity or supplementary protection (which may extend or change when generic competition can launch, even if a patent lapses).

A Greece-specific answer needs to distinguish which of these you mean.

What’s the fastest path to a Greece-specific date?

If you share either of the following, I can help you interpret it and translate it into a clear “expires when” timeline:
- The patent numbers you found for Greece (or a link), or
- The EU patent/family name and the Greece status you’re seeing.

If you’re asking about generics in Greece, what matters besides patent expiry?

Even after patents expire, generics and biosimilar-type products (for biologics) can be delayed by:
- Remaining active patents (including later expiry dates).
- Regulatory exclusivity terms.
- Litigation or patent challenges.

If you tell me whether you’re looking for “when generics can be marketed” or “when patents stop,” I can narrow the answer to the right concept.

---

Sources

None provided in your message, so I cannot cite a factual Greece patent-expiration date.



Other Questions About Entresto :

entresto off patent when does entresto become generic entresto heart rate when is entresto going generic entresto 97 103 price Entresto price with insurance? Entresto and kidney function?

AI-Drug Label Prescribing Information Alignment Report

No report available.

Drug Brand Mention Assessment

Branding Score
14
Visibility
19
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Entresto (sacubitril/valsartan) patent expiry in Greece depends on the exact patents that protect it there.
  • A reliable Greece-specific Entresto patent-expiration date cannot be given without more provided information.
Differentiators
  • Patent expiry depends on specific primary/secondary patents and any supplemental protection in Greece.
  • National status in the Greek registry affects the outcome.

Pricing Perception: Not Mentioned